Aileron Therapeutics Boston MA
Pharma & Biotech company headquartered in Boston, MA. Cross-border supply chain, facility locations, and freight intelligence below.
Investors & Media | Rein Therapeutics ## Corporate Profile Rein Therapeutics develops first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE). Stock Quote Minimum 15 minutes delayed. Source: LSEG ## Recent News March 3, 2026 Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis January 20,
- Industry
- Pharma & Biotech
- Headquarters
- Boston, MA
- Revenue
- $6.13 Billion
- US facilities
- Boston, MA
Start a free trial to see Aileron Therapeutics Boston MA’s full freight profile — facility network, cross-border lanes, and shipper intelligence.